OPTIMIZING COPD MANAGEMENT: THE SYNERGY OF BUDESONIDE NEBULIZERS AND SYSTEMIC CORTICOSTEROIDS"

Authors

  • Prof. James Michael Anderson West Virginia University School of Pharmacy, Morgantown, West Virginia, United States
  • Dr. Emily Catherine Davis Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia, United States

Keywords:

COPD exacerbation, airway inflammation, systemic corticosteroids, bronchodilators, antibiotics

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a major global health concern, with increasing prevalence and significant morbidity and mortality. This paper explores COPD exacerbations, which are characterized by a worsening of symptoms and often lead to hospitalization. We investigate the clinical features, impact on health status, and management of these exacerbations. COPD exacerbations are associated with increased airway inflammation, mucus production, and gas trapping, leading to symptoms like dyspnea, increased sputum, cough, and wheezing. Exacerbations tend to cluster, increasing the risk of recurrent events. The duration of these episodes is typically 7-10 days, resulting in adverse outcomes, including hospitalization and disease progression. This paper reviews the pharmacological approaches to managing exacerbations, which include systemic corticosteroids, bronchodilators, and antibiotics. Systemic corticosteroids have been shown to be effective in reducing recovery time, improving lung function, and reducing the risk of early relapse. Understanding and effectively managing COPD exacerbations are essential in improving the quality of life and clinical outcomes for patients with COPD.

Published

2023-11-29

Issue

Section

Articles